Crude and age-adjusted vaccine effectiveness (VE) estimates for genital wart by number of qHPV vaccine doses, time since vaccination and age at first vaccine dose.

Estimation of the impact of genital warts on health-related quality of life.

Woodhall, S
Ramsey, T
Cai, C
Crouch, S
Jit, M
Birks, Y
Edmunds, WJ
Newton, R
Lacey, CJN

January 2008

OBJECTIVES: One of the two new human papillomavirus (HPV) vaccines protects against HPV types 6 and ...

Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches

Donken, R.
Hoes, J.
Knol, M. J.
Ogilvie, G. S.
Dobson, S.
King, A. J.
Singer, J.
Woestenberg, P. J.
Bogaards, J. A.
Meijer, C. J. L. M.
de Melker, H. E.

July 2020

BackgroundPersistent high-risk human papillomavirus (HPV) infection is endorsed by the World Health ...

High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years after Vaccination in Young Dutch Women

Donken, R.
King, A. J.
Bogaards, J. A.
Woestenberg, P. J.
Meijer, C. J. L. M.
de Melker, H. E.

January 2018

Background Monitoring vaccine effectiveness (VE) in vaccination programs is of importance for assess...

Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.

Geraldine Dominiak-Felden
Corrado Gobbo
François Simondon

Genital warts (GWs) are common, with about 5% to 10% of people having at least one episode in their ...

Impact of the HPV vaccination programme.

Geraldine Dominiak-Felden (765449)
Corrado Gobbo (765450)
François Simondon (80294)

July 2015

Age- and gender-standardised genital warts incidence rates estimates in the pre-vaccination (2006...

Estimated HPV 6/11 related incidence of genital warts among females over 100 years, by vaccination scenario.

Ana Patricia Ortiz (505999)
Karen J. Ortiz-Ortiz (559636)
Moraima Ríos (4633696)
José Laborde (4633684)
Amit Kulkarni (116474)
Matthew Pillsbury (4633690)
Andreas Lauschke (4633693)
Homero A. Monsanto (4633687)
Cecile Marques-Goyco (4633699)

November 2017

Estimated HPV 6/11 related incidence of genital warts among females over 100 years, by vaccinatio...

Effectiveness of HPV vaccine by age at vaccination and number of doses: protocol for a population-based matched case–control study

Carlos R Oliveira
Anette Michelle Ortiz
Sangini S Sheth
Eugene D Shapiro
Linda M Niccolai

April 2021

Introduction In 2006, the first human papillomavirus (HPV) vaccine was approved by the Food and Drug...

Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study.

Leval, Amy
Herweijer, Eva
Ploner, Alexander
Eloranta, Sandra
Fridman Simard, Julia
Dillner, Joakim
Young, Cecilia
Netterlid, Eva
Sparén, Pär
Arnheim-Dahlström, Lisen

January 2013

BackgroundIncidence of condyloma, or genital warts (GW), is the earliest possible disease outcome to...

Effectiveness of qHPV vaccination in women 24–45 years of age against HPV 6/11/16/18-related CIN or condyloma (cumulative incidence in the EVG, day 1 to year 6).

Joaquin Luna (504103)
Manuel Plata (504104)
Mauricio Gonzalez (2081956)
Alfonso Correa (504105)
Ivete Maldonado (504106)
Claudia Nossa (504107)
David Radley (504108)
Scott Vuocolo (504109)
Richard M. Haupt (504110)
Alfred Saah (504111)

December 2013

N = Number of subjects in the indicated group who received at least 1 dose of the qHPV vaccine.</...

Incidence of genital warts per 100 000 individuals (dashed line: females; solid line: males) and qHPV vaccine uptake in individuals aged 16–22 years (A), 23–30 years (B), 31–40 years (C) and 41–59 years (D) affiliated to the MLOZ sick fund (Belgium) between 2006 and 2013 (standardised estimates).

Geraldine Dominiak-Felden (765449)
Corrado Gobbo (765450)
François Simondon (80294)

July 2015

Incidence of genital warts per 100 000 individuals (dashed line: females; solid line: males) and ...

Vaccine Effectiveness Following Routine Immunization With Bivalent Human Papillomavirus (HPV) Vaccine: Protection Against Incident Genital HPV Infections From a Reduced-Dosing Schedule

Hoes, Joske
King, Audrey J.
Klooster, Tessa M. Schurink Van't
Berkhof, Johannes
Bogaards, Johannes A.
de Melker, Hester E.

September 2022

BACKGROUND: In the Netherlands, the bivalent human papillomavirus (HPV) vaccine has been offered to ...

Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands

Woestenberg, Petra J
King, Audrey J
Van Benthem, Birgit H B
Leussink, Suzan
Van der Sande, Marianne A B
Hoebe, Christian J P A
Bogaards, Johannes A

April 2020

Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vacci...

Measuring vaccine effectiveness against persistent HPV infections:a comparison of different statistical approaches

Donken, R.
Hoes, J.
Knol, M. J.
Ogilvie, G. S.
Dobson, S.
King, A. J.
Singer, J.
Woestenberg, P. J.
Bogaards, J. A.
Meijer, C. J. L. M.
de Melker, H. E.

July 2020

BackgroundPersistent high-risk human papillomavirus (HPV) infection is endorsed by the World Health ...

Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands

Woestenberg, Petra J.
King, Audrey J.
Van Benthem, Birgit H.B.
Leussink, Suzan
Van Der Sande, Marianne A.B.
Hoebe, Christian J.P.A.
Bogaards, Johannes A.

January 2020

Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vacci...

Efficacy of Vaccination against HPV Infections to Prevent Cervical Cancer in France: Present Assessment and Pathways to Improve Vaccination Policies

Ribassin-Majed Laureen
Lounes Rachid
Clémençon Stephan

March 2012

Seventy percent of sexually active individuals will be infected with Human Papillomavirus (HPV) duri...

Estimation of the impact of genital warts on health-related quality of life.

Woodhall, S
Ramsey, T
Cai, C
Crouch, S
Jit, M
Birks, Y
Edmunds, WJ
Newton, R
Lacey, CJN

January 2008

OBJECTIVES: One of the two new human papillomavirus (HPV) vaccines protects against HPV types 6 and ...

Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches

Donken, R.
Hoes, J.
Knol, M. J.
Ogilvie, G. S.
Dobson, S.
King, A. J.
Singer, J.
Woestenberg, P. J.
Bogaards, J. A.
Meijer, C. J. L. M.
de Melker, H. E.

July 2020

BackgroundPersistent high-risk human papillomavirus (HPV) infection is endorsed by the World Health ...

High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years after Vaccination in Young Dutch Women

Donken, R.
King, A. J.
Bogaards, J. A.
Woestenberg, P. J.
Meijer, C. J. L. M.
de Melker, H. E.

January 2018

Background Monitoring vaccine effectiveness (VE) in vaccination programs is of importance for assess...

Evaluating the Early Benefit of Quadrivalent HPV Vaccine on Genital Warts in Belgium: A Cohort Study.

Geraldine Dominiak-Felden
Corrado Gobbo
François Simondon

Genital warts (GWs) are common, with about 5% to 10% of people having at least one episode in their ...

Impact of the HPV vaccination programme.

Geraldine Dominiak-Felden (765449)
Corrado Gobbo (765450)
François Simondon (80294)

July 2015

Age- and gender-standardised genital warts incidence rates estimates in the pre-vaccination (2006...

Estimated HPV 6/11 related incidence of genital warts among females over 100 years, by vaccination scenario.

Ana Patricia Ortiz (505999)
Karen J. Ortiz-Ortiz (559636)
Moraima Ríos (4633696)
José Laborde (4633684)
Amit Kulkarni (116474)
Matthew Pillsbury (4633690)
Andreas Lauschke (4633693)
Homero A. Monsanto (4633687)
Cecile Marques-Goyco (4633699)

November 2017

Estimated HPV 6/11 related incidence of genital warts among females over 100 years, by vaccinatio...

Effectiveness of HPV vaccine by age at vaccination and number of doses: protocol for a population-based matched case–control study

Carlos R Oliveira
Anette Michelle Ortiz
Sangini S Sheth
Eugene D Shapiro
Linda M Niccolai

April 2021

Introduction In 2006, the first human papillomavirus (HPV) vaccine was approved by the Food and Drug...

Quadrivalent Human Papillomavirus Vaccine Effectiveness: A Swedish National Cohort Study.

Leval, Amy
Herweijer, Eva
Ploner, Alexander
Eloranta, Sandra
Fridman Simard, Julia
Dillner, Joakim
Young, Cecilia
Netterlid, Eva
Sparén, Pär
Arnheim-Dahlström, Lisen

January 2013

BackgroundIncidence of condyloma, or genital warts (GW), is the earliest possible disease outcome to...

Effectiveness of qHPV vaccination in women 24–45 years of age against HPV 6/11/16/18-related CIN or condyloma (cumulative incidence in the EVG, day 1 to year 6).

Joaquin Luna (504103)
Manuel Plata (504104)
Mauricio Gonzalez (2081956)
Alfonso Correa (504105)
Ivete Maldonado (504106)
Claudia Nossa (504107)
David Radley (504108)
Scott Vuocolo (504109)
Richard M. Haupt (504110)
Alfred Saah (504111)

December 2013

N = Number of subjects in the indicated group who received at least 1 dose of the qHPV vaccine.</...

Incidence of genital warts per 100 000 individuals (dashed line: females; solid line: males) and qHPV vaccine uptake in individuals aged 16–22 years (A), 23–30 years (B), 31–40 years (C) and 41–59 years (D) affiliated to the MLOZ sick fund (Belgium) between 2006 and 2013 (standardised estimates).

Geraldine Dominiak-Felden (765449)
Corrado Gobbo (765450)
François Simondon (80294)

July 2015

Incidence of genital warts per 100 000 individuals (dashed line: females; solid line: males) and ...

Vaccine Effectiveness Following Routine Immunization With Bivalent Human Papillomavirus (HPV) Vaccine: Protection Against Incident Genital HPV Infections From a Reduced-Dosing Schedule

Hoes, Joske
King, Audrey J.
Klooster, Tessa M. Schurink Van't
Berkhof, Johannes
Bogaards, Johannes A.
de Melker, Hester E.

September 2022

BACKGROUND: In the Netherlands, the bivalent human papillomavirus (HPV) vaccine has been offered to ...

Bivalent Vaccine Effectiveness Against Anal Human Papillomavirus Positivity Among Female Sexually Transmitted Infection Clinic Visitors in the Netherlands

Woestenberg, Petra J
King, Audrey J
Van Benthem, Birgit H B
Leussink, Suzan
Van der Sande, Marianne A B
Hoebe, Christian J P A
Bogaards, Johannes A

April 2020

Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vacci...

Measuring vaccine effectiveness against persistent HPV infections:a comparison of different statistical approaches

Donken, R.
Hoes, J.
Knol, M. J.
Ogilvie, G. S.
Dobson, S.
King, A. J.
Singer, J.
Woestenberg, P. J.
Bogaards, J. A.
Meijer, C. J. L. M.
de Melker, H. E.

July 2020

BackgroundPersistent high-risk human papillomavirus (HPV) infection is endorsed by the World Health ...

Bivalent vaccine effectiveness against anal human papillomavirus positivity among female sexually transmitted infection clinic visitors in the netherlands

Woestenberg, Petra J.
King, Audrey J.
Van Benthem, Birgit H.B.
Leussink, Suzan
Van Der Sande, Marianne A.B.
Hoebe, Christian J.P.A.
Bogaards, Johannes A.

January 2020

Human papillomavirus (HPV) vaccines are indicated for anal cancer prevention, but evidence for vacci...

Efficacy of Vaccination against HPV Infections to Prevent Cervical Cancer in France: Present Assessment and Pathways to Improve Vaccination Policies

Ribassin-Majed Laureen
Lounes Rachid
Clémençon Stephan

March 2012

Seventy percent of sexually active individuals will be infected with Human Papillomavirus (HPV) duri...

Estimation of the impact of genital warts on health-related quality of life.

Woodhall, S
Ramsey, T
Cai, C
Crouch, S
Jit, M
Birks, Y
Edmunds, WJ
Newton, R
Lacey, CJN

January 2008

OBJECTIVES: One of the two new human papillomavirus (HPV) vaccines protects against HPV types 6 and ...

Measuring vaccine effectiveness against persistent HPV infections: a comparison of different statistical approaches

Donken, R.
Hoes, J.
Knol, M. J.
Ogilvie, G. S.
Dobson, S.
King, A. J.
Singer, J.
Woestenberg, P. J.
Bogaards, J. A.
Meijer, C. J. L. M.
de Melker, H. E.

July 2020

BackgroundPersistent high-risk human papillomavirus (HPV) infection is endorsed by the World Health ...

High Effectiveness of the Bivalent Human Papillomavirus (HPV) Vaccine Against Incident and Persistent HPV Infections up to 6 Years after Vaccination in Young Dutch Women

Donken, R.
King, A. J.
Bogaards, J. A.
Woestenberg, P. J.
Meijer, C. J. L. M.
de Melker, H. E.

January 2018

Background Monitoring vaccine effectiveness (VE) in vaccination programs is of importance for assess...

Crude and age-adjusted vaccine effectiveness (VE) estimates for genital wart by number of qHPV vaccine doses, time since vaccination and age at first vaccine dose.

Abstract

Extracted data

Crude and age-adjusted vaccine effectiveness (VE) estimates for genital wart by number of qHPV vaccine doses, time since vaccination and age at first vaccine dose.

Abstract

Extracted data

Related items

Related items